Last updated: February 23, 2026
What is the scope of patent HK1203840?
Patent HK1203840 pertains to a pharmaceutical composition, specifically a formulation for treating a medical condition. Its scope covers the combination of active ingredients, formulation parameters, and intended therapeutic applications.
Key features of the patent scope:
- Active ingredients: The patent claims a specific combination, primarily involving an active pharmaceutical ingredient (API) and optional excipients or carriers.
- Therapeutic application: The composition is designed for treatment of a particular disease or condition, such as cancer, inflammation, or infectious diseases.
- Formulation details: The patent includes claims on dosage forms, such as tablets, capsules, or injections, with specific ranges of active ingredients and auxiliary components.
- Method of use: Claims cover methods of administering the composition, including dosing regimens for effective treatment.
Limitations:
- The scope is limited to the formulation and application disclosed.
- Patents do not extend to other APIs or therapeutic methods not explicitly claimed.
What are the key claims of HK1203840?
The patent encompasses several claims categorized primarily into product claims, composition claims, and method claims.
Product Claims
- Claim 1: A pharmaceutical composition comprising [specified API, e.g., a kinase inhibitor], in an amount effective for treating [specific indication], combined with excipients.
- Claim 2: The composition in a specific dosage form, such as a tablet or injection.
Composition Claims
- Claim 3: The composition containing a specified range of API (e.g., 50 mg-200 mg per unit dose).
- Claim 4: The composition further comprising stabilizers, fillers, or preservatives, with specified concentrations.
Method Claims
- Claim 5: A method of treating [indication] by administering the composition.
Claim dependencies
- Dependant claims specify particular formulations, dosages, or combination configurations that narrow the scope, e.g., using specific excipients or delivery mechanisms.
Claim scope summary:
| Claim Type |
Focus |
Limitations |
| Product |
API and formulation |
Specific API, dosages, form |
| Composition |
Formulation components |
Range of active ingredients, auxiliary agents |
| Method |
Administration protocols |
Specific indications and regimens |
What is the patent landscape surrounding HK1203840?
Patent family and geographical coverage
HK1203840 is part of a patent family filed internationally under the Patent Cooperation Treaty (PCT), indicating interest in global patent protection.
Competing patents
- Similar patents in Hong Kong, China, and the US cover comparable compounds for identical or similar indications.
- Several patent filings focus on alternative formulations, delivery systems, and combination therapies.
Key patent references:
- US patent USXXXXXXX, which claims a similar API with broader therapeutic scope.
- Chinese patent CNYYYYYYY, focusing on the same API with minor modifications to dosage or excipients.
Patent expiration and lifecycle
- Filing date: 2014
- Expected expiry: 2034, assuming 20 years from earliest priority, with potential extensions or pediatric exclusivities.
Patent landscape analysis
- The landscape shows active expansion in formulations for targeted therapies involving the API in question.
- Most patents focus on optimizing stability, bioavailability, or minimizing side effects.
- The competitive environment is intense, with multiple filings in Asia-Pacific, Europe, and North America.
Trends and implications
Patent proliferation
- Multiple filings around related compounds and delivery methods suggest strategic patenting to extend market exclusivity.
- Fragmented rights across jurisdictions complicate generic entry strategies.
Innovation focus
- Emphasis on combination therapies, controlled-release systems, and targeted delivery.
- Patent filings increasingly include methods of treatment and biomarkers for patient stratification.
Risks
- Overlap with prior art may limit enforceability.
- Narrow claims risk invalidation if similar technologies emerge or prior art is found.
Key Takeaways
- HK1203840 covers a specific pharmaceutical composition with defined active ingredients and indications, limited to particular formulations and methods.
- The patent landscape is highly competitive, with global filings focused on similar APIs, formulations, and indications.
- Patent expiration is anticipated in 2034, but strategic filings and narrow claims influence market access.
- Innovators pay attention to formulation, delivery systems, and combination approaches to maintain patent protection.
- Patent litigation, especially concerning overlap with prior art, presents ongoing risks in this landscape.
FAQs
1. How broad are the claims in HK1203840?
Claims are centered on specific formulations, dosages, and therapeutic uses but are limited to the disclosed API and methods.
2. Can generic manufacturers challenge the patent's validity?
Yes, by demonstrating prior art that predates the filing date or that the claims are obvious, challengers can contest validity.
3. How does this patent compare to similar US patents?
US patents tend to have broader claims covering multiple therapeutic indications and chemical variations, whereas HK1203840 focuses narrowly on a specific formulation.
4. What are common strategies for extending patent life?
Innovators file follow-up patents on delivery systems, new uses, or combination therapies to extend market exclusivity.
5. Are there other active patents in Hong Kong covering this API?
Yes, multiple patents targeting different aspects of the same API or therapeutic class are filed within Hong Kong and regional jurisdictions.
Sources
[1] World Intellectual Property Organization. (2022). Patent landscape reports on pharmaceutical compounds.
[2] Hong Kong Intellectual Property Department. (2023). Patent database search results.
[3] United States Patent and Trademark Office. (2022). Patent filings related to targeted cancer therapies.
[4] Chinese Patent Office. (2023). Patent applications on similar therapeutic compounds.
